Genentech, part of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today encouraging topline results from the one-year Phase IV ELEVATUM study. This open-label, single-arm trial evaluated Vabysmo® (faricimab-svoa)…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, recently shared encouraging outcomes from its Phase 2b/3 clinical trial (MK-1654-004) of clesrovimab, a monoclonal antibody aimed at preventing…
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced that Health Canada has granted marketing authorization for DAYBUE™ (trofinetide) to treat Rett syndrome in patients aged two and older. This approval, under…
Airway Therapeutics, Inc. has announced the launch of a multinational Phase 3 clinical trial for zelpultide alfa (rhSP-D). This study aims to prevent bronchopulmonary dysplasia (BPD) and mitigate lung injury…
MEDiC Life Sciences, a prominent functional genomics startup in Silicon Valley, has announced a $5M strategic investment from LG and Hanmi Pharmaceutical. This funding precedes MEDiC’s upcoming Series-A round later…
Genentech, part of the Roche Group, shared encouraging two-year data from the ongoing RAINBOWFISH study at the 29th World Muscle Society Congress (October 8-12, 2024). This study evaluated the efficacy…
Foundation Medicine, Inc. has announced FDA approval for FoundationOne® Liquid CDx as a companion diagnostic for Itovebi™ (inavolisib) when used with palbociclib (Ibrance®) and fulvestrant. This therapy, developed by Genentech,…
Paige, a leader in next-generation AI technology, has announced that its foundation models will be showcased by Microsoft at the HLTH 2024 conference in Las Vegas. On October 21st, Matt…
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has announced the acceptance of four abstracts for the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics,…
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced that it presented data demonstrating the effectiveness of sebetralstat in reducing anxiety during hereditary angioedema (HAE) attacks at the HAEi Global Angioedema Forum (GAF)…
A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company focused on developing first-in-class logic-gated cell therapies to selectively target tumor cells while protecting healthy cells, has announced that six…
Exact Sciences Corp. (NASDAQ: EXAS), a prominent provider of cancer screening and diagnostic solutions, has announced that the U.S. Food and Drug Administration (FDA) has approved its next-generation multitarget stool…